

# CITATION REPORT

List of articles citing

**The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis**

**DOI: 10.1093/cid/ciaa1592**

**Clinical Infectious Diseases, 2021, 72, e901-e913.**

**Source:** <https://exaly.com/paper-pdf/77814339/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
29	COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. <i>Nature Reviews Nephrology</i> , <b>2020</b> , 16, 747-764	14.9	229
28	Conflicts over calcium and the treatment of COVID-19. <i>Evolution, Medicine and Public Health</i> , <b>2021</b> , 9, 149-156	3	12
27	The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension. <i>PLoS ONE</i> , <b>2021</b> , 16, e0248652	3.7	4
26	Role of Serine Proteases and Host Cell Receptors Involved in Proteolytic Activation, Entry of SARS-CoV-2 and Its Current Therapeutic Options. <i>Infection and Drug Resistance</i> , <b>2021</b> , 14, 1883-1892	4.2	5
25	Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia. <i>Korean Journal of Internal Medicine</i> , <b>2021</b> , 36, 617-628	2.5	1
24	Late phase of COVID-19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 3483-3494	3.7	8
23	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	6
22	Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	4
21	Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 2223-2239	3.6	5
20	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. <i>CJC Open</i> , <b>2021</b> , 3, 965-975	2	5
19	Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality. <i>Systematic Reviews</i> , <b>2021</b> , 10, 243	3	1
18	Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis. <i>Therapeutic Advances in Drug Safety</i> , <b>2021</b> , 12, 20420986211011345	3.5	4
17	ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
16	The Impact of COVID-19 on Patients With ADPKD. <i>Canadian Journal of Kidney Health and Disease</i> , <b>2021</b> , 8, 20543581211056479	2.3	
15	Cardiac Manifestations in Patients with COVID-19: A Scoping Review.. <i>Global Heart</i> , <b>2022</b> , 17, 2	2.9	2
14	Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials.. <i>American Journal of Hypertension</i> , <b>2022</b> , 35, 462-469	2.3	1
13	Interactions of renin-angiotensin system and COVID-19: the importance of daily rhythms in ACE2, ADAM17 and TMPRSS2 expression.. <i>Physiological Research</i> , <b>2021</b> , 70, S177-S194	2.1	6

12	An umbrella review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 outcomes: what do we know so far?.		
11	COVID-19 in renal transplant recipients and general population: a comparative study of clinical, laboratory, and radiological features, severity, and outcome. <i>Virology Journal</i> , <b>2021</b> , 18, 243	6.1	1
10	Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.. <i>Drugs</i> , <b>2021</b> , 82, 43	12.1	1
9	COVID-19 and acute myocardial injury: Stem cell driven tissue remodeling in COVID-19 infection. <b>2022</b> , 111-124		
8	The Effect of ACEI/ARB on the Outcomes of COVID-19 Hospitalized Patients. <i>Nephro-Urology Monthly</i> , <b>2022</b> , 14,	0.4	
7	Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research. <i>Journal of the American Heart Association</i> ,	6	1
6	Why antidiabetic drugs are potentially neuroprotective during the Sars-CoV-2 pandemic: The focus on astroglial UPR and calcium-binding proteins. 16,		0
5	Association of outpatient use of renin-angiotensin-aldosterone system blockers on outcomes of acute respiratory illness during the COVID-19 pandemic: a cohort study. <b>2022</b> , 12, e060305		1
4	Determinants of COVID-19 Breakthrough Infections and Severity in ChAdOx1 nCoV-19 Vaccinated Priority Groups. <b>2022</b> ,		
3	An umbrella review and meta-analysis of renin-angiotensin system drugs use and COVID -19 outcomes.		1
2	Effects of previous exposure to different medications on the clinical course of COVID-19 patients in Istanbul, Turkey. <b>2023</b> , 7, 79-85		0
1	Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity. <b>2023</b> , 42, 373-383		1